UBS Lowers CANSINOBIO (06185) Target Price to HK$52.4, Q1 Results In Line

Stock News04-30

UBS has released a research report stating that CANSINOBIO's (06185) first-quarter performance for the year met expectations. During the period, revenue reached 190 million yuan, representing a year-on-year increase of 38.7%, slightly surpassing the bank's forecast of 34% growth for the full year 2026. The net loss was 40 million yuan, compared to the bank's full-year 2024 profit forecast of 337 million yuan. UBS adjusted its earnings per share forecasts for the group for 2026 to 2028, revising them down from the original 1.36 yuan, 2.26 yuan, and 3.77 yuan to 0.77 yuan, 2.15 yuan, and 3.58 yuan, respectively. The target price was reduced from HK$59.8 to HK$52.4, while maintaining a "Buy" rating.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1171896997?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-30 16:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1171896997","market":"us","top_or_hot":-1,"title":"UBS Lowers CANSINOBIO (06185) Target Price to HK$52.4, Q1 Results In Line","media":"Stock News","content":"<p>UBS has released a research report stating that CANSINOBIO's (06185) first-quarter performance for the year met expectations. During the period, revenue reached 190 million yuan, representing a year-on-year increase of 38.7%, slightly surpassing the bank's forecast of 34% growth for the full year 2026. The net loss was 40 million yuan, compared to the bank's full-year 2024 profit forecast of 337 million yuan. UBS adjusted its earnings per share forecasts for the group for 2026 to 2028, revising them down from the original 1.36 yuan, 2.26 yuan, and 3.77 yuan to 0.77 yuan, 2.15 yuan, and 3.58 yuan, respectively. The target price was reduced from HK$59.8 to HK$52.4, while maintaining a \"Buy\" rating.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>UBS Lowers CANSINOBIO (06185) Target Price to HK$52.4, Q1 Results In Line</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUBS Lowers CANSINOBIO (06185) Target Price to HK$52.4, Q1 Results In Line\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-04-30 16:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>UBS has released a research report stating that CANSINOBIO's (06185) first-quarter performance for the year met expectations. During the period, revenue reached 190 million yuan, representing a year-on-year increase of 38.7%, slightly surpassing the bank's forecast of 34% growth for the full year 2026. The net loss was 40 million yuan, compared to the bank's full-year 2024 profit forecast of 337 million yuan. UBS adjusted its earnings per share forecasts for the group for 2026 to 2028, revising them down from the original 1.36 yuan, 2.26 yuan, and 3.77 yuan to 0.77 yuan, 2.15 yuan, and 3.58 yuan, respectively. The target price was reduced from HK$59.8 to HK$52.4, while maintaining a \"Buy\" rating.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"EWH","symbol_name":"香港ETF-iShares MSCI","start_time":0,"source_url":"","article_id":"1171896997","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1171896997","pubTimestamp":1777537001,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"UBS has released a research report stating that CANSINOBIO's (06185) first-quarter performance for the year met expectations. During the period, revenue reached 190 million yuan, representing a...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"EWH":"香港ETF-iShares MSCI","BK1515":"抗疫概念","BK1191":"制药","BK1161":"生物科技","06185":"康希诺生物","BK1574":"生物医药B类股"},"translate_title":"瑞银下调康希诺生物(06185)目标价至52.4港元Q1业绩符合","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EWH":1,"06185":1},"content_text":"UBS has released a research report stating that CANSINOBIO's (06185) first-quarter performance for the year met expectations. During the period, revenue reached 190 million yuan, representing a year-on-year increase of 38.7%, slightly surpassing the bank's forecast of 34% growth for the full year 2026. The net loss was 40 million yuan, compared to the bank's full-year 2024 profit forecast of 337 million yuan. UBS adjusted its earnings per share forecasts for the group for 2026 to 2028, revising them down from the original 1.36 yuan, 2.26 yuan, and 3.77 yuan to 0.77 yuan, 2.15 yuan, and 3.58 yuan, respectively. The target price was reduced from HK$59.8 to HK$52.4, while maintaining a \"Buy\" rating.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1171896997","isCrawlerRequest":true}